Your browser doesn't support javascript.
loading
Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner.
Gertz, Morie; Adams, David; Ando, Yukio; Beirão, João Melo; Bokhari, Sabahat; Coelho, Teresa; Comenzo, Raymond L; Damy, Thibaud; Dorbala, Sharmila; Drachman, Brian M; Fontana, Marianna; Gillmore, Julian D; Grogan, Martha; Hawkins, Philip N; Lousada, Isabelle; Kristen, Arnt V; Ruberg, Frederick L; Suhr, Ole B; Maurer, Mathew S; Nativi-Nicolau, Jose; Quarta, Candida Cristina; Rapezzi, Claudio; Witteles, Ronald; Merlini, Giampaolo.
Afiliación
  • Gertz M; Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. gertz.morie@mayo.edu.
  • Adams D; Referral Center for FAP, Neurology Department, APHP, INSERM U 1195, Université Paris-Sud, Le Kremlin Bicêtre, France.
  • Ando Y; Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Beirão JM; Ophthalmology Service, Hospital de Santo António, Porto, Portugal.
  • Bokhari S; Columbia University Medical Center, New York, NY, USA.
  • Coelho T; Centro Hospitalar do Porto, Porto, Portugal.
  • Comenzo RL; John C. Davis Myeloma and Amyloid Program, Tufts Medical Center, Boston, MA, USA.
  • Damy T; Department of Cardiology, Referral Center for Cardiac Amyloidosis, GRC Amyloid Research Institute, DHU A-TVB, APHP CHU Henri Mondor and Université Paris Est Créteil, Créteil, France.
  • Dorbala S; Brigham and Women's Hospital, Boston, MA, USA.
  • Drachman BM; University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
  • Fontana M; National Amyloidosis Centre, University College London, London, UK.
  • Gillmore JD; National Amyloidosis Centre, University College London, London, UK.
  • Grogan M; Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
  • Hawkins PN; National Amyloidosis Centre, University College London, London, UK.
  • Lousada I; Amyloidosis Research Consortium, Newton, MA, USA.
  • Kristen AV; University of Heidelberg, Heidelberg, Germany.
  • Ruberg FL; Boston University School of Medicine, Boston Medical Center, Boston, MA, USA.
  • Suhr OB; Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
  • Maurer MS; Columbia University Medical Center, New York, NY, USA.
  • Nativi-Nicolau J; University of Utah Health, Salt Lake City, UT, USA.
  • Quarta CC; National Amyloidosis Centre, University College London, London, UK.
  • Rapezzi C; University of Bologna, Bologna, Italy.
  • Witteles R; Stanford Amyloid Center, Stanford University School of Medicine, Stanford, California, USA.
  • Merlini G; Amyloidosis Research and Treatment Center Foundation, IRCCS Policlinico San Matteo, San Matteo, Italy.
BMC Fam Pract ; 21(1): 198, 2020 09 23.
Article en En | MEDLINE | ID: mdl-32967612
BACKGROUND: Transthyretin amyloidosis (also known as ATTR amyloidosis) is a systemic, life-threatening disease characterized by transthyretin (TTR) fibril deposition in organs and tissue. A definitive diagnosis of ATTR amyloidosis is often a challenge, in large part because of its heterogeneous presentation. Although ATTR amyloidosis was previously considered untreatable, disease-modifying therapies for the treatment of this disease have recently become available. This article aims to raise awareness of the initial symptoms of ATTR amyloidosis among general practitioners to facilitate identification of a patient with suspicious signs and symptoms. METHODS: These consensus recommendations for the suspicion and diagnosis of ATTR amyloidosis were developed through a series of development and review cycles by an international working group comprising key amyloidosis specialists. This working group met to discuss the barriers to early and accurate diagnosis of ATTR amyloidosis and develop a consensus recommendation through a thorough search of the literature performed using PubMed Central. RESULTS: The cardiac and peripheral nervous systems are most frequently involved in ATTR amyloidosis; however, many patients often also experience gastrointestinal and other systemic manifestations. Given the multisystemic nature of symptoms, ATTR amyloidosis is often misdiagnosed as a more common disorder, leading to significant delays in the initiation of treatment. Although histologic evaluation has been the gold standard to confirm ATTR amyloidosis, a range of tools are available that can facilitate early and accurate diagnosis. Of importance, genetic testing should be considered early in the evaluation of a patient with unexplained peripheral neuropathy. CONCLUSIONS: A diagnostic algorithm based on initial red flag symptoms and manifestations of cardiac or neurologic involvement will facilitate identification by the general practitioner of a patient with clinically suspicious symptoms, enabling subsequent referral of the patient to a multidisciplinary specialized medical center.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neuropatías Amiloides Familiares / Médicos Generales Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: BMC Fam Pract Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neuropatías Amiloides Familiares / Médicos Generales Tipo de estudio: Diagnostic_studies / Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: BMC Fam Pract Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos